Developers are delivering exceptional spaces that meet the needs of innovative life sciences companies today, with consideration for their growth aspirations well into the future, supported by local knowledge and connections.
In 2022, Mission Street and BentallGreenOak announced the acquisition of 1 Temple Way in central Bristol with plans to deliver the largest commercial science development in the South-West.
The Joint Venture, formed in January 2021, has been scaling in key areas across the UK that are anchored by strong research and development credentials. This is their first acquisition outside Oxford and Cambridge.
Invest Bristol & Bath, the West of England Combined Authority’s inward investment service, played a key role helping prepare their business case, demonstrating the demand and potential growth in the region’s life sciences sector. It also connected the businesses with the life sciences and deep tech ecosystem with introductions to the universities and incubators.
With planning consent for 135,000 sq. ft of NIA (net internal area), 1 Temple Way will have the scale to support the emerging R&D and deep tech ecosystem in Bristol with wet lab, dry lab and high-specification office space. The development, designed by Allford Hall Monaghan Morris, gained planning consent in April 2022.
1 Temple Way is an iconic building originally built in 1974 for the Bristol United Press and was highly innovative for its time. It is in the heart of Bristol’s emerging tech and science district, near the University of Bristol’s new Enterprise Campus and close to Temple Meads station. The industrial qualities of the building, having originally been developed for a printworks, provide the large floor plates, resilient structure and floor-to-ceiling heights ideally suited for R&D use, which is unique for city centre office buildings.